[go: up one dir, main page]

BR112015025852A2 - as formulações de oxabicicloheptanos e oxabicicloheptenos - Google Patents

as formulações de oxabicicloheptanos e oxabicicloheptenos

Info

Publication number
BR112015025852A2
BR112015025852A2 BR112015025852A BR112015025852A BR112015025852A2 BR 112015025852 A2 BR112015025852 A2 BR 112015025852A2 BR 112015025852 A BR112015025852 A BR 112015025852A BR 112015025852 A BR112015025852 A BR 112015025852A BR 112015025852 A2 BR112015025852 A2 BR 112015025852A2
Authority
BR
Brazil
Prior art keywords
oxabicycloheptenes
oxabicycloheptanes
formulations
pp2a
pharmaceutical composition
Prior art date
Application number
BR112015025852A
Other languages
English (en)
Inventor
S Kovach John
L Wells Mickey
Original Assignee
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc filed Critical Lixte Biotechnology Inc
Publication of BR112015025852A2 publication Critical patent/BR112015025852A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo as formulações de oxabicicloheptanos e oxabicicloheptenos a invenção refere-se a uma composição farmacêutica compreendendo uma proteína fosfatase 2a (pp2a) de inibidor e glutamato de monossódio.
BR112015025852A 2013-04-09 2014-04-08 as formulações de oxabicicloheptanos e oxabicicloheptenos BR112015025852A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361810053P 2013-04-09 2013-04-09
PCT/US2014/033317 WO2014168941A1 (en) 2013-04-09 2014-04-08 Formulations of oxabicycloheptanes and oxabicycloheptenes

Publications (1)

Publication Number Publication Date
BR112015025852A2 true BR112015025852A2 (pt) 2017-07-25

Family

ID=51689953

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025852A BR112015025852A2 (pt) 2013-04-09 2014-04-08 as formulações de oxabicicloheptanos e oxabicicloheptenos

Country Status (14)

Country Link
US (3) US10532050B2 (pt)
EP (1) EP2983661B1 (pt)
JP (1) JP2016516772A (pt)
KR (1) KR20160004299A (pt)
CN (1) CN105209036B (pt)
AU (1) AU2014251087B2 (pt)
BR (1) BR112015025852A2 (pt)
CA (1) CA2909160C (pt)
EA (1) EA201591931A1 (pt)
ES (1) ES2984267T3 (pt)
HK (1) HK1221416A1 (pt)
MX (1) MX2015014249A (pt)
PH (1) PH12015502331A1 (pt)
WO (1) WO2014168941A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
CA2876703A1 (en) * 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
CA2877167A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
MX2015014249A (es) * 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
KR102375396B1 (ko) 2014-05-13 2022-03-18 노파르티스 아게 연골형성을 유도하기 위한 화합물 및 조성물
WO2015196073A1 (en) * 2014-06-20 2015-12-23 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
US20170209434A1 (en) 2014-07-24 2017-07-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
CN107072991A (zh) * 2014-09-12 2017-08-18 莱克斯特生物技术公司 磷酸酶抑制剂的人类给药
US9833450B2 (en) * 2015-02-19 2017-12-05 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
CA2986104A1 (en) * 2015-05-15 2016-11-24 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs
US20190111053A1 (en) * 2016-01-27 2019-04-18 Lixte Biotechnology, Inc. Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
KR20190098995A (ko) * 2016-12-08 2019-08-23 릭스트 바이오테크놀로지, 인코포레이티드 면역 반응의 조절을 위한 옥사바이사이클로헵탄
CN116710093A (zh) * 2021-01-19 2023-09-05 利克斯特生物技术公司 用于治疗小细胞肺癌的氧杂二环庚烷
WO2022232135A1 (en) * 2021-04-28 2022-11-03 The University Of Toledo Methods of treating cancer and ischemia diseases by inhibition and intervention of atr prolyl isomerization

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2957906A (en) 1955-10-25 1960-10-25 Monsanto Chemicals Ketones
US3227473A (en) 1963-12-12 1966-01-04 Julian S Halbern Check identification
JPS5752354B2 (pt) 1973-10-22 1982-11-06
JPS5069091U (pt) 1973-10-25 1975-06-19
US3980674A (en) 1974-01-28 1976-09-14 Delmar Chemicals Limited 2,3-Disubstituted 7-oxabicyclo-[2.2.1]-5-heptene
JPS5132733A (en) 1974-09-10 1976-03-19 Kyowa Hakko Kogyo Kk Josozai
US3954913A (en) 1975-01-06 1976-05-04 The Standard Oil Company Stabilized nitrile polymers
JPS5188631U (pt) 1975-01-10 1976-07-15
JPS5188631A (en) 1975-01-31 1976-08-03 Hiiryoyosatsukinzai oyobi sonoseizoho
US4143054A (en) 1977-11-04 1979-03-06 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane- and 7-oxabicycloheptene compounds
US4218478A (en) 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
US4760067A (en) * 1979-08-15 1988-07-26 Merck & Co., Inc. Allylsulfoxide enzyme inhibitors
US4298752A (en) 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US4614825A (en) 1982-05-17 1986-09-30 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane and 7-oxabicycloheptene compounds
US4463015A (en) 1982-08-18 1984-07-31 E. R. Squibb & Sons, Inc. Aryl substituted 7-oxabicycloheptane compounds, useful in inhibiting platelet aggregation
US4518696A (en) * 1983-01-11 1985-05-21 Chr. Hansen's Laboratory, Inc. Stabilized liquid bacterial suspension for oral administration to animals
US4524151A (en) 1983-11-14 1985-06-18 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptane thio ethers useful as cardiovascular agents
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US4654355A (en) 1985-08-01 1987-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted amide-thioamide prostaglandin analogs
US4851553A (en) 1986-06-04 1989-07-25 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane amido-carboxylic acids
US4816579A (en) 1986-06-04 1989-03-28 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane amino-alcohol intermediates useful in making thromboxane A2 receptor antagonists
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
SU1553533A1 (ru) 1988-01-28 1990-03-30 Военная Краснознаменная академия химической защиты им.Маршала Советского Союза С.К.Тимошенко Способ получени 1,4-бисполифторалкил-7-оксбицикло [2.2.1]гептанов
JP2789365B2 (ja) 1988-12-14 1998-08-20 塩野義製薬株式会社 ジカルボン酸モノエステルおよびその製造法
RU2015980C1 (ru) 1990-02-06 1994-07-15 Е.Р.Сквибб энд Санз, Инк. 7-оксабициклогептилзамещенные гетероциклические амиды или их стереоизомеры в качестве антагонистов рецепторов тромбоксана
US5763647A (en) 1990-03-30 1998-06-09 Shionogi & Co., Ltd. Preparation of optically active 1,4-bridged-cyclohexane carboxylic acid derivatives
EP0536163A1 (en) 1990-06-04 1993-04-14 Pfizer Inc. Aromatic pyrrolidine and thiazolidine amides
US5266710A (en) 1990-12-18 1993-11-30 Patel Ramesh N (Exo,exo)-7-oxabicyclo[2.2.1]heptane-2,3-dimethanol; monoacyl ester and diacyl ester
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
JP3134233B2 (ja) * 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α−グリコシル ケルセチンとその製造方法並びに用途
US5326898A (en) 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
US6602713B1 (en) 2001-02-09 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5518993A (en) 1994-08-12 1996-05-21 Buckman Laboratories International, Inc. Pesticidal compositions containing ethoxylated fatty amines for increasing the effectiveness of endothal and salts thereof
US5770382A (en) 1994-12-30 1998-06-23 Ligand Pharmaceuticals, Inc. Tricyclic retinoids, methods for their production and use
US6222055B1 (en) 1995-07-06 2001-04-24 Fraunhofer-Gesellschaft Zur Foerderung Der Angwandten Forschung E.V. Hydrolyzable and polymerizable and/or polyadditive silanes
DE19600707B4 (de) 1996-01-11 2004-02-19 Glüsenkamp, Karl-Heinz, Dr. Biyclische Anhydrid-Wirkstoff-Verbindungen, Verfahren zur Herstellung und Verwendung derselben
US5968965A (en) 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5925651A (en) 1996-04-03 1999-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
DK2018858T3 (da) 1997-10-15 2013-01-07 Polarx Biopharmaceuticals Inc Sammensætninger og fremgangsmåder til behandlingen af primære og metastatiske neoplastiske sygdomme ved anvendelse af arsentrioxid
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
JP2002516880A (ja) 1998-06-05 2002-06-11 テクニオン リサーチ アンド デベロップメント ファウンデーション リミテッド インスリンを補った乳児用調製乳
AUPP466598A0 (en) 1998-07-14 1998-08-06 University Of Newcastle Research Associates Limited, The Product and process
US20040110822A1 (en) 1998-07-14 2004-06-10 The University Of Newcastle Research Associates Anhydride modified cantharidin analogues useful in the treatment of cancer
AU772373B2 (en) 1998-08-07 2004-04-22 Laboratoires Serono Sa FSH mimetics for the treatment of infertility
US20020151515A1 (en) 1999-06-18 2002-10-17 Roberts Bruce L. Preparation and use of superior vaccines
US6949624B1 (en) 1999-08-03 2005-09-27 The United States Of America As Represented By The Department Of Health And Human Services Cloning of the human nuclear receptor co-repressor gene
JP2003509343A (ja) 1999-09-08 2003-03-11 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 新規クラスの細胞分化剤およびヒストンデアセチラーゼならびにそれらの使用方法
US7605185B2 (en) 1999-11-23 2009-10-20 Gerhart Graupner Treatment of arrhythmia by retinoids affecting signal transduction
WO2001062242A1 (en) 2000-02-24 2001-08-30 Biocryst Pharmaceuticals, Inc. Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
JP4518627B2 (ja) 2000-03-14 2010-08-04 旭化成イーマテリアルズ株式会社 ヒドロキシポリアミド
JP2003528074A (ja) 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
DE10038043B4 (de) 2000-08-02 2006-09-07 Walter, Michael, Dr. Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60112312T2 (de) 2000-09-21 2005-12-29 Smithkline Beecham P.L.C., Brentford Imidazolderivate als raf-kinase-inhibitoren
WO2002028387A1 (en) 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2001296661A1 (en) 2000-10-06 2002-04-15 Michigan State University Divinyl ether synthase gene and protein, and uses thereof
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US20020177692A1 (en) 2001-04-16 2002-11-28 Myriad Genetics, Incorporated BCL-XL-interacting protein and use thereof
AU2002242175A1 (en) 2001-02-16 2002-09-04 Brigham And Women's Hospital Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
DE10122898A1 (de) * 2001-05-11 2002-11-14 Haarmann & Reimer Gmbh Verwendung von Hydroxyflavanonen zur Maskierung des bitteren Geschmacks
US20070015144A9 (en) 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
AU2002322721B2 (en) 2001-08-03 2009-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US7179450B2 (en) 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
WO2003032921A2 (en) 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
ATE352319T1 (de) 2001-11-06 2007-02-15 Novartis Pharma Gmbh Kombination cyclooxygenase-2 inhibitor/ histone deacetylase inhibitor
AU2002353845A1 (en) 2001-11-23 2003-06-10 Eli Lilly And Company Prodrugs of excitatory amino acids
JP2004035408A (ja) * 2002-02-15 2004-02-05 Chiron Corp テザシタビンを含有する安定な組成物
AU2003211576A1 (en) 2002-02-20 2003-09-09 Sueharu Horinouchi Histone deacetylase inhibitors and process for producing the same
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7375059B2 (en) 2002-03-08 2008-05-20 Basf Aktiengesellschaft Fungicidal mixtures based on prothioconazole and containing an insecticide
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
IL149404A0 (en) 2002-04-29 2002-11-10 Yissum Res Dev Co METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
WO2003092616A2 (en) 2002-05-01 2003-11-13 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
WO2003097835A2 (en) 2002-05-16 2003-11-27 Molecular Engines Laboratories Pharmaceutical compositions for the treatment of cancer
MXPA05003119A (es) 2002-09-23 2005-06-22 Schering Corp Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
AU2003291736A1 (en) 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
US20040197888A1 (en) * 2002-12-31 2004-10-07 Armour Christopher D. Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
US20050222013A1 (en) 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
EP1601965A4 (en) 2003-03-12 2010-11-10 Samaritan Pharmaceuticals Inc SIMULATION OF NEUROLOGICAL DISEASES WITH ANIMAL MODEL
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
WO2005025620A2 (en) 2003-08-13 2005-03-24 Pharmacia Corporation Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
JP2007502287A (ja) 2003-08-13 2007-02-08 アムジェン インコーポレイテッド メラニン凝集ホルモン受容体アンタゴニスト
US20070135365A1 (en) 2003-08-21 2007-06-14 Katsuyuki Tanizawa Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiovascular disease caused thereby
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7094193B2 (en) 2003-08-28 2006-08-22 Philip Morris Usa Inc. High speed laser perforation of cigarette tipping paper
EP1670466A4 (en) 2003-10-06 2007-04-25 Glaxo Group Ltd PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
AU2004283313A1 (en) 2003-10-24 2005-05-06 Exelixis, Inc. TAO kinase modulators and methods of use
EP1691891A2 (en) 2003-11-13 2006-08-23 The Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
GB0328157D0 (en) 2003-12-04 2004-01-07 Imp College Innovations Ltd Compounds
EP1699436A2 (en) 2003-12-12 2006-09-13 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
US8652502B2 (en) 2003-12-19 2014-02-18 Cordis Corporation Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
EP1715870A1 (en) 2004-02-02 2006-11-02 Myogen, Inc. Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
CN1586500A (zh) 2004-07-19 2005-03-02 俞锋 治疗肿瘤的斑蝥酸钠注射剂及其制备方法
AU2005277384B2 (en) 2004-08-17 2011-11-17 The Johns Hopkins University PDE5 inhibitor compositions and methods for treating cardiac indications
WO2006052842A2 (en) 2004-11-09 2006-05-18 The Trustees Of The University Of Pennsylvania Methods for diagnosis of myelodysplastic syndromes (mds)
KR100677149B1 (ko) 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
US20060264415A1 (en) 2005-04-01 2006-11-23 Methylgene Inc. Inhibitors of histone deacetylase
CN1304396C (zh) * 2005-04-08 2007-03-14 中山大学 斑蝥素衍生物及其制备方法
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1945242A2 (en) 2005-07-22 2008-07-23 The Regents of the University of Colorado, A Body Corporate Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
EP1915141A1 (en) 2005-08-10 2008-04-30 Novartis AG Method of use of deacetylase inhibitors
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
WO2007072179A2 (en) 2005-12-19 2007-06-28 Methylgene, Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
WO2007092414A2 (en) 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Use of phosphatases to treat tumors overexpressing n-cor
CA2648804C (en) 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US20090018142A9 (en) 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
US20080267947A1 (en) 2006-09-07 2008-10-30 Cirrito Thomas P Cancer therapy with cantharidin and cantharidin analogs
WO2008028965A2 (en) 2006-09-08 2008-03-13 Institut Gustave Roussy Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
US20080097561A1 (en) 2006-10-18 2008-04-24 Medcool, Inc. Dual cycle thermal system and method of use
CA2670259A1 (en) 2006-11-15 2008-05-22 Genetic Technologies Limited Compounds, compositions and methods for controlling invertebrate pests
BRPI0806365B8 (pt) * 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
US8413445B2 (en) 2007-05-11 2013-04-09 General Electric Company Method and system for porous flame holder for hydrogen and syngas combustion
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
EP2185173A4 (en) 2007-08-03 2011-01-12 Lixte Biotechnology Inc USE OF PHOSPHATASES FOR THE TREATMENT OF NEUROBLASTOMES AND MEDULLOGASTOMES
JP5730575B2 (ja) 2007-10-01 2015-06-10 リクスト・バイオテクノロジー，インコーポレイテッド Ｈｄａｃ阻害剤
JP5069091B2 (ja) 2007-12-12 2012-11-07 三菱電機株式会社 監視カメラおよび監視カメラシステム
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
AU2009277179A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
CA2734908A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
CN101367783A (zh) 2008-10-10 2009-02-18 中国科学技术大学 5-羟甲基糠醛的制备方法
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
US20120135522A1 (en) 2009-06-18 2012-05-31 Kovach John S Methods of modulating cell regulation by inhibiting p53
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
MX2012012225A (es) 2010-04-23 2013-08-27 Piramal Entpr Ltd Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
CA2836940A1 (en) 2011-05-24 2012-11-29 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
WO2013056211A2 (en) 2011-10-13 2013-04-18 H. Lee Moffitt Cancer Center & Research Institute, Inc. Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome
SG11201407973SA (en) 2012-06-01 2015-01-29 Taisho Pharmaceutical Co Ltd Prodrug of fluorine-containing amino acid
CA2877167A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
CA2876703A1 (en) 2012-06-29 2014-01-03 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury
US9738933B2 (en) 2012-12-05 2017-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
EP2964026A4 (en) 2013-03-05 2016-08-17 Lixte Biotechnology Inc HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY
WO2014149494A1 (en) 2013-03-15 2014-09-25 Lixte Biotechnology, Inc. Sanguinarine analog pp2c inhibitors for cancer treatment
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
JP2016538281A (ja) 2013-11-15 2016-12-08 リクスト・バイオテクノロジー，インコーポレイテッド 血液脳関門を通過するタンパク質ホスファターゼ阻害剤
US9051332B1 (en) 2013-11-20 2015-06-09 Transitions Optical, Inc. Photochromic indeno-fused ring pyran compounds
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015254949A1 (en) 2014-04-28 2016-10-06 Alembic Pharmaceuticals Limited Novel polymorphic forms of Vortioxetine and its pharmaceutically acceptable salts
WO2015196073A1 (en) 2014-06-20 2015-12-23 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
US20170209434A1 (en) 2014-07-24 2017-07-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
CN107072991A (zh) 2014-09-12 2017-08-18 莱克斯特生物技术公司 磷酸酶抑制剂的人类给药
US9994584B2 (en) * 2014-10-15 2018-06-12 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
US9833450B2 (en) 2015-02-19 2017-12-05 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
MX390954B (es) 2015-04-17 2025-03-21 Bristol Myers Squibb Co Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CA2986104A1 (en) 2015-05-15 2016-11-24 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs
IL297003A (en) 2015-09-17 2022-12-01 Novartis Ag Car t cell therapies with enhanced efficacy
US20190111053A1 (en) 2016-01-27 2019-04-18 Lixte Biotechnology, Inc. Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
KR20190098995A (ko) 2016-12-08 2019-08-23 릭스트 바이오테크놀로지, 인코포레이티드 면역 반응의 조절을 위한 옥사바이사이클로헵탄
WO2019113155A1 (en) 2017-12-05 2019-06-13 Lixte Biotechnology, Inc. Oxabicycloheptanes for treatment of secondary acute myeloid leukemia
WO2019241536A1 (en) 2018-06-14 2019-12-19 Lixte Biotechnology, Inc. Oxabicycloheptanes for enhancing car t cell function
RU201598U1 (ru) 2020-05-14 2020-12-22 Андрей Владимирович Дмитриев Безреагентная испарительная градирня
CN116710093A (zh) 2021-01-19 2023-09-05 利克斯特生物技术公司 用于治疗小细胞肺癌的氧杂二环庚烷
WO2023133371A2 (en) 2022-01-04 2023-07-13 Lixte Biotechnology, Inc. Compositions and methods for treating cancer or preventing, inhibiting or reducing risk of metastasis of a cancer

Also Published As

Publication number Publication date
US20160051544A1 (en) 2016-02-25
CN105209036A (zh) 2015-12-30
EP2983661C0 (en) 2024-05-29
EP2983661A4 (en) 2016-12-21
AU2014251087A1 (en) 2015-11-19
CA2909160C (en) 2021-05-25
CN105209036B (zh) 2018-10-26
CA2909160A1 (en) 2014-10-16
US11931354B2 (en) 2024-03-19
WO2014168941A1 (en) 2014-10-16
PH12015502331A1 (en) 2016-02-22
US10532050B2 (en) 2020-01-14
ES2984267T3 (es) 2024-10-29
US20240041864A1 (en) 2024-02-08
EA201591931A1 (ru) 2016-05-31
MX2015014249A (es) 2016-06-02
JP2016516772A (ja) 2016-06-09
EP2983661A1 (en) 2016-02-17
AU2014251087B2 (en) 2019-05-02
HK1221416A1 (zh) 2017-06-02
KR20160004299A (ko) 2016-01-12
US20200179375A1 (en) 2020-06-11
EP2983661B1 (en) 2024-05-29

Similar Documents

Publication Publication Date Title
BR112015025852A2 (pt) as formulações de oxabicicloheptanos e oxabicicloheptenos
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX380250B (es) Compuestos farmacéuticos inhibidores de cinasa chk-1.
CY1119489T1 (el) Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
UY35306A (es) Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina.
EP3364944C0 (en) PHARMACEUTICAL COMPOSITIONS OF IL-2
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
MX382624B (es) Compuestos farmacéuticos.
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112016020181A2 (pt) Composições de ácido lipoico éster colina e métodos de uso.
CO6650346A2 (es) Composiciones de tetraciclina
MX373320B (es) Compuestos inhibidores de pde2.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CR20160448A (es) Nuevos derivados de piridina
EP3980005A4 (en) CARBACHOL-BRIMONIDINE FORMULATION FOR IMPROVING ANTI-PRESBYOPIA EFFECTS
UY35690A (es) Composiciones farmacéuticas de ranolazina y dronedarona
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]